Passionate about what we do, and having worked together for many years, we have maintained exceptional values within our team, across our unrivalled network of contacts and for our clients.
We are a people business.
Supriya is an experienced communications professional with over 17 years’ of advising clients in financial communications and investor relations, in the UK and overseas. Having worked in both agency and in-house, she has significant expertise in developing and implementing communications strategies to support business and project objectives, and is a media relations specialist with strong entrepreneurial, project and team management skills.
Supriya has implemented global media and investor relations campaigns for clients across healthcare, technology and financial services. She has worked on numerous transactions including fundraisings, M&A and IPOs.
Hollie specialises in providing financial and corporate communications support to a wealth of private and public healthcare companies both in the UK and in Europe.
With over 7 years experience, Hollie has managed and implemented successful IR and PR programmes for her clients, providing support on everything from financial calendar work, investor roadshows and analyst briefings, perception studies and event management to support on major strategic deals and transactions including fundraisings, M&A and IPOs. She also provides media relations expertise to her clients, working across print, online and broadcast media.
Anne Marieke Ezendam
Mary has a 20-year successful track record in providing strategic corporate and financial communications to both early- and late-stage healthcare companies.
She has run several high profile PR campaigns and has been instrumental in assisting companies with strategic positioning and fundraising rounds from seed and private financings through IPOs, reverse mergers, as well as numerous follow-on public financings.
Mary has worked with over 100 healthcare clients across Europe and the US including Teva Pharmaceutical, Bayer, Fresenius Medical Care, Kite Pharmaceuticals, UDG Healthcare, Evotec and BioNTech.
Mary has built and led healthcare businesses at several international PR&IR agencies. She started her career at BTG plc where she was involved in the Company’s IPO and the start-up of several new tech and biotech companies.
Anne Marieke Ezendam
Anne Marieke has over 20 years’ experience as a buyside fund manager and analyst responsible for investing across the global healthcare sector. She joins Optimum from Amundi Asset Management, Europe’s largest asset manager and top ten firm globally. She joined Amundi as deputy head of the Global Equity team in January 2014 and was responsible for setting up the team’s research platform. Prior to this, Anne Marieke was responsible for global healthcare at ING Investment Management, Credit Suisse Asset Management, Threadneedle Asset Management and Gulf International Bank. She also helped set up the European franchise for Cross Current Research LLC. Anne Marieke started her career as a medical sales representative at Roche and 3M Pharmaceuticals in the Netherlands. She graduated in Biology with Medical Specialisation from the University of Utrecht.
Dr Niall Kirk
Eva has 20 years’ experience in fund management and company analysis across the global healthcare sector. She lived in New York for 7 years covering the US. She was recently at Schroder Investment management where she was responsible for the analysis and valuation of publicly listed & about-to-be-listed healthcare companies in medical devices & supplies, diagnostics, biotechnology, pharma, life sciences tools, healthcare distribution, pharmacy benefit management, hospitals & health insurance.
Eva has a PhD in Biochemistry from Bristol University. She is also a fluent German speaker.
Dr Niall Kirk
Niall has over 20 years’ experience in analyzing and investing in a wide range of healthcare companies, from biotechnology start-ups to pharma, medtech, generic and healthcare service companies. He was at F&C Asset Management managing the global healthcare funds and advising other F&C funds on the healthcare sector. Prior to this he was at Commerzbank as a biotechnology analyst.
He started his career in healthcare consulting specializing in business development between pharmaceutical and biotechnology firms. He went on to build up the due diligence unit, particularly for biotechnology company IPOs on the London market.
Jonathan has over 25 years’ experience in the City as a sellside analyst at SG Warburg/UBS and Redburn, specialising in the pharmaceutical sector. Latterly, at Redburn, he managed the proprietary research service, in-house and for institutional clients.
Jonathan has established and run several companies with a broad range of products and services.
Nick has over 23 years’ of experience advising a wide range of international and UK companies on a broad range of multi-stakeholder communications programmes. Financial market communications is a core strength and he has advised both UK and non-UK listed companies on their communications to both equity and debt investors.
He has helped many companies at key moments of change, whether making their market debut, raising capital (he has helped companies raise more than US$30bn), during transformational acquisitions (he has advised on transactions worth more than US$100bn), or ensuring accurate understanding of the drivers behind their performance. He has particular experience of message development, presentation development, management rehearsal, annual report messaging and drafting, financial reporting, financial media relations preparation and delivery.
Seasoned all-round communication professional and director with a strong strategic and financial profile. Long-time experience in taking responsibility for leading communication roles in crises, international merger & acquisitions, sustainability, Initial Private Offerings, as well as building and leading an integrated communications and investor relations department.
Broad corporate experience as Director Corporate Communications & Investor Relations of Delta Lloyd NV, Amsterdam from 2002 until 2016 (listed in Amsterdam and Brussels). Previously held communications management functions for Corus Group plc (since 2007 part of Tata Steel), in the Netherlands and London and Dutch steel company Koninklijke Hoogovens NV (1998-2001).
An experience investor relations professional with over 20 years’ experience. Leti has 15 years of Equity Capital Markets/Corporate Broking experience from various capital markets, where IR has always been an important focus. She also spent 4 years as a Communication consultant, focused on crisis communication and media relations.
Experience in doing IR work for exchanges: IR-trained Romanian IPO candidates on behalf of the Bucharest Stock Exchange. She has spent 4 years in Geneva (IR, fundraisings for pre-IPO, IPO and public cos), 2 years in Zurich (IR and IPO strategic advisory). She is fluent in French and Italian.
Our partner in the USA, Burns McClellan, based in New York
Dedicated exclusively to the life sciences industry, offering a comprehensive approach to public and investor relations.
Our partner in the Nordics, Cord Communications, based in Stockholm
Providing expert advice and execution to clients in a wide range of PR-related needs and IR-related issues for both public and non-listed companies.
Optimum Strategic Communications is looking to expand the team in London.
We have openings for a graduate/post graduate level Account Executive and an ambitious Account Manager to join our thriving team.
We are always looking for talented people who can think strategically and work creatively. Whether you’re an established strategic communications practitioner or looking to start your career in investor relations and PR – we want to hear from you.